Written question asked by Blake Stephenson (Conservative) on Tuesday, 11 February 2025, in the House of Commons. It was due for an answer on Thursday, 13 February 2025. It was answered by Feryal Clark (Labour) on Wednesday, 19 February 2025 on behalf of the Department for Science, Innovation and Technology.
AstraZeneca: Merseyside
- Question
-
To ask the Secretary of State for Science, Innovation and Technology, whether he has conducted a lessons learned review over negotiations with AstraZeneca on proposed investment in Merseyside.
- Answer
-
AstraZeneca’s decision not to invest in Speke is deeply disappointing. The Government regularly reviews it’s grant process and routinely seeks applicant feedback. The Government also continues to engage positively with AstraZeneca, including on the new Industrial Strategy and Life Sciences Sector Plan, due to be published in late Spring. This will set out a comprehensive plan of how the Government intends to drive growth in the sector. Support includes the Life Sciences Innovative Manufacturing Fund, which will allocate up to £520 million to deliver economic growth and build health resilience.
Secondary information
- Type
- Written question
- Reference
- 30737
- Session
- 2024-26
- Related items
- Transferred
- Yes
- Subjects
- Investment Merseyside AstraZeneca
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2025-09-05 19:28:40 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-25/30737
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-25/30737
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-25/30737